About Kadmon Holdings (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
Industry, Sector and Symbol:
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Sector: Biopharmaceuticals
- Symbol: NYSE:KDMN
- CUSIP: N/A
- Web: kadmon.com
- Current Ratio: 1.30%
- Quick Ratio: 1.29%
Sales & Book Value:
- Annual Sales: $26.06 million
- Price / Sales: 11.17
- Book Value: ($0.44) per share
- Price / Book: -8.41
- Trailing EPS: ($1.75)
- Net Income: ($208,750,000.00)
- Net Margins: -555.91%
- Return on Assets: -124.91%
- Employees: 118
- Outstanding Shares: 78,640,000
Frequently Asked Questions for Kadmon Holdings (NYSE:KDMN)
What is Kadmon Holdings' stock symbol?
Kadmon Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon Holdings' earnings last quarter?
Kadmon Holdings, Inc. (NYSE:KDMN) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.04. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $5.69 million. The company's quarterly revenue was down 60.0% on a year-over-year basis. During the same period last year, the firm posted ($4.24) earnings per share. View Kadmon Holdings' Earnings History.
Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?
5 brokers have issued 1 year target prices for Kadmon Holdings' shares. Their predictions range from $3.00 to $25.00. On average, they expect Kadmon Holdings' stock price to reach $9.75 in the next twelve months. View Analyst Ratings for Kadmon Holdings.
Are investors shorting Kadmon Holdings?
Kadmon Holdings saw a decline in short interest in October. As of October 13th, there was short interest totalling 1,298,965 shares, a decline of 35.9% from the September 29th total of 2,026,862 shares. Based on an average trading volume of 654,970 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.0% of the shares of the stock are sold short.
Who are some of Kadmon Holdings' key competitors?
Some companies that are related to Kadmon Holdings include Sinovac Biotech (SVA), 3SBio (SSRX), ChemoCentryx (CCXI), Syros Pharmaceuticals (SYRS), Mereo BioPharma Group PLC (MPH), Strongbridge Biopharma PLC (SBBP), Syndax Pharmaceuticals (SNDX), Peregrine Pharmaceuticals (PPHM), Kamada (KMDA), Fortress Biotech (FBIO), Mirna Therapeutics (SYBX), MediWound (MDWD), Vericel Corporation (VCEL), KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT) and Cardiome Pharma Corporation (CRME).
When did Kadmon Holdings IPO?
(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Who owns Kadmon Holdings stock?
Kadmon Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
GOLDENTREE ASSET MANAGEMENT LP
PUISSANCE CROSS-BORDER OPPORTUNITIES IV LLC
(5.93%), Sphera Funds Management LTD. (1.40%), Crestline Management LP (0.76%), AE Wealth Management LLC (0.41%) and Wells Fargo & Company MN (0.09%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon Holdings.
Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?
Kadmon Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Crestline Management LP, AE Wealth Management LLC, Old West Investment Management LLC, Bank of New York Mellon Corp and Wells Fargo & Company MN. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon Holdings.
How do I buy Kadmon Holdings stock?
Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon Holdings' stock price today?
One share of Kadmon Holdings stock can currently be purchased for approximately $3.70.
How big of a company is Kadmon Holdings?
Kadmon Holdings has a market capitalization of $290.19 million and generates $26.06 million in revenue each year. The company earns ($208,750,000.00) in net income (profit) each year or ($1.75) on an earnings per share basis. Kadmon Holdings employs 118 workers across the globe.
How can I contact Kadmon Holdings?
Kadmon Holdings' mailing address is 450 E 29th St, NEW YORK, NY 10016-8367, United States. The company can be reached via phone at +1-212-3086000 or via email at [email protected]
MarketBeat Community Rating for Kadmon Holdings (NYSE KDMN)MarketBeat's community ratings are surveys of what our community members think about Kadmon Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Kadmon Holdings (NYSE:KDMN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.40)|
|Consensus Price Target: ||$9.75 (163.51% upside)|
Consensus Price Target History for Kadmon Holdings (NYSE:KDMN)
Analysts' Ratings History for Kadmon Holdings (NYSE:KDMN)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/17/2017||HC Wainwright||Reiterated Rating||Buy||$25.00||N/A|
|10/9/2017||WBB Securities||Downgrade||Hold -> Sell||$3.00||N/A|
|8/2/2017||Piper Jaffray Companies||Set Price Target||Buy||$7.00||Medium|
|3/27/2017||Citigroup Inc.||Lower Price Target||Neutral||$6.00 -> $4.00||High|
|11/21/2016||JMP Securities||Reiterated Rating||Buy||N/A|
|11/10/2016||Jefferies Group LLC||Reiterated Rating||Buy||$12.00 -> $10.00||N/A|
Earnings History and Estimates Chart for Kadmon Holdings (NYSE:KDMN)
Earnings History by Quarter for Kadmon Holdings (NYSE KDMN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.38)||($0.42)||$5.69 million||$2.28 million||View||N/A|
|8/3/2017||Q2 2017||($0.49)||($0.44)||$3.46 million||$3.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.52)||($0.39)||$4.25 million||$5.60 million||View||N/A|
|3/22/2017||Q4 2016||($0.71)||($0.50)||$4.50 million||$4.28 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($4.23)||$3.90 million||$5.70 million||View||N/A|
Earnings Estimates for Kadmon Holdings (NYSE:KDMN)
Current Year EPS Consensus Estimate: $-1.63 EPS
Next Year EPS Consensus Estimate: $-1.78 EPS
Dividend History for Kadmon Holdings (NYSE:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Kadmon Holdings (NYSE KDMN)
Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 27.52%
Insider Trades by Quarter for Kadmon Holdings (NYSE KDMN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/6/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||302,950||$2.73||$827,053.50|| |
|8/10/2017||Harlan Waksal||CEO||Buy||5,000||$2.27||$11,350.00|| |
|8/8/2017||Eugene Bauer||Director||Buy||5,000||$2.36||$11,800.00|| |
|8/8/2017||Harlan Waksal||CEO||Buy||3,707||$2.34||$8,674.38|| |
|8/8/2017||Steven N. Gordon||VP||Buy||1,000||$2.47||$2,470.00|| |
|7/31/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||349,661||$2.60||$909,118.60|| |
|7/11/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||34,462||$3.69||$127,164.78|| |
|6/29/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||64,375||$4.04||$260,075.00|| |
|6/27/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||108,827||$3.69||$401,571.63|| |
|6/26/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||515,643||$3.51||$1,809,906.93|| |
|6/22/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||767,363||$3.50||$2,685,770.50|| |
|3/13/2017||Daniel S Loeb||Major Shareholder||Buy||1,488,095||$3.36||$4,999,999.20|| |
|11/16/2016||Harlan Waksal||CEO||Buy||2,000||$6.37||$12,740.00|| |
|11/14/2016||Harlan Waksal||CEO||Buy||2,000||$6.79||$13,580.00|| |
|11/11/2016||Konstantin Poukalov||CFO||Buy||4,000||$5.81||$23,240.00|| |
|9/14/2016||Daniel S Loeb||Major Shareholder||Buy||19,611||$7.79||$152,769.69|| |
|9/13/2016||Daniel S Loeb||Major Shareholder||Buy||68,654||$8.33||$571,887.82|| |
|9/6/2016||Daniel S Loeb||Major Shareholder||Buy||81,781||$9.39||$767,923.59|| |
|8/26/2016||Daniel S Loeb||Major Shareholder||Buy||32,916||$9.98||$328,501.68|| |
|8/22/2016||Daniel S Loeb||Major Shareholder||Buy||11,305||$10.00||$113,050.00|| |
|8/15/2016||Daniel S Loeb||Major Shareholder||Buy||6,010||$9.95||$59,799.50|| |
|8/12/2016||Daniel S Loeb||Major Shareholder||Buy||87,529||$9.98||$873,539.42|| |
|8/5/2016||Daniel S Loeb||Major Shareholder||Buy||66,828||$9.94||$664,270.32|| |
|8/3/2016||Daniel S Loeb||Major Shareholder||Buy||1,431,996||$11.35||$16,253,154.60|| |
|8/1/2016||Goldentree Asset Management Lp||Major Shareholder||Buy||208,333||$12.00||$2,499,996.00|| |
|7/28/2016||Bart M Schwartz||Director||Buy||2,000||$9.77||$19,540.00|| |
Headline Trends for Kadmon Holdings (NYSE:KDMN)
Latest Headlines for Kadmon Holdings (NYSE KDMN)
Kadmon Holdings (NYSE KDMN) Chart for Saturday, November, 18, 2017